The 3-year axillary RFS rate was 99.2% with axillary lymph node dissection and 98.8% with less-invasive procedures. Less-invasive lymph node procedures are noninferior to axillary lymph node ...
Dublin, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The "Endoscopic Submucosal Dissection Market - A Global and Regional Analysis: Focus on Indication, Product, End user, Country, and Region - Analysis and ...
Background: Currently, the axillary management strategy of omitting axillary lymph node dissection (ALND) in early-stage breast cancer (BC) patients with cT1-2, clinically node-negative (cN0), and ...
D. Scott Lind, M.D., F.A.C.S.; Barbara L. Smith, M.D., Ph.D., F.A.C.S.; Wiley W. Souba, M.D., Sc.D., F.A.C.S. Before the advent of SLN biopsy, axillary dissection was ...
Patients with clinically node-negative breast cancer after neoadjuvant chemotherapy demonstrated low axillary and locoregional recurrence rates after sentinel lymph node biopsy (SLNB) or targeted ...
NAC facilitates tumor downsizing, enabling breast-conserving surgery and improving overall survival by achieving pathologic complete response (pCR). Landmark trials, such as NSABP B-18 and EORTC 10994 ...
SAN ANTONIO -- Patients with early breast cancer who skipped axillary lymph node dissection (ALND) lived just as long as those who underwent sentinel lymph node biopsy (SLNB), the randomized INSEMA ...
Please provide your email address to receive an email when new articles are posted on . Patients with early invasive breast cancer who did not receive axillary surgery had noninferior outcomes as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback